Trial Profile
A Randomized, Double Blind, Placebo-Controlled Study to Assess Efficacy, Safety and Tolerability of ISIS 304801 in Patients With Partial Lipodystrophy With an Open-Label Extension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Volanesorsen (Primary)
- Indications Lipodystrophy
- Focus Therapeutic Use
- 23 Mar 2021 Results assessing within-subject effects of Volanesorsen lipids, glycemia and lipolysis, before and after 16 weeks of active drug, presented at the 103rd Annual Meeting of the Endocrine Society.
- 27 Sep 2019 Status changed from active, no longer recruiting to completed.
- 25 Jan 2019 Planned primary completion date changed from 31 Dec 2018 to 31 Dec 2019.